Amgen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

11.09.17	EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine (PR Newswire)
09.09.17	Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress (PR Newswire)
08.09.17	Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High (RTTNews)
07.09.17	New Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies (PR Newswire)
07.09.17	Amgen To Present At The Morgan Stanley Global Healthcare Conference (PR Newswire)
07.09.17	CH2M named to Fortune's Top 50 Companies that Change the World (PR Newswire)
07.09.17	AstraZeneca Announces Results From PATHWAY Phase IIb Trial Of Tezepelumab (RTTNews)
06.09.17	Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma (PR Newswire)
05.09.17	Decline in Pharmacy Customer Satisfaction Driven by Prescription Drug Costs, J.D. Power Finds (PR Newswire)
31.08.17	European Commission Approves Expanded Use Of Mimpara® (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis (PR Newswire)
31.08.17	Digital Realty to Present at Investor Conferences in September 2017 (PR Newswire)
31.08.17	AMGN's Endeavor Awaits Verdict, NVS Scripts History, OTIC Is Not Music To Ears (RTTNews)
30.08.17	Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma (PR Newswire)
30.08.17	FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS® (Carfilzomib) Label (PR Newswire)
29.08.17	New Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke (PR Newswire)
29.08.17	New Virtual Histology Sub-Study Evaluates Impact Of Repatha® (Evolocumab) On Coronary Artery Plaque Composition (PR Newswire)
29.08.17	Biotech Stocks Facing FDA Decision In September (RTTNews)
28.08.17	Amgen Reports New Repatha Analysis - Quick Facts (RTTNews)
28.08.17	New Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels (PR Newswire)
24.08.17	Amgen Foundation Expands The Amgen Biotech Experience, Bringing Total Program Reach To 900,000 High School Students By 2020 (PR Newswire)
24.08.17	Overall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology (PR Newswire)
23.08.17	New Economic Analysis Based On Repatha® (Evolocumab) Outcomes Data Published In JAMA Cardiology (PR Newswire)
21.08.17	Amgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017 (PR Newswire)
18.08.17	FDA Nod For PFE, New Use For AZN's Ovarian Cancer Drug, ELGX's LEOPARD Hits Goal (RTTNews)
16.08.17	Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine (PR Newswire)
08.08.17	Scottish Medicines Consortium Accepts Amgen's Multiple Myeloma Treatment, KYPROLIS® ▼ (carfilzomib), in Combination with Dexamethasone, for use at First Relapse (PR Newswire)
31.07.17	Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis (PR Newswire)
31.07.17	Amgen And Allergan Submit Biosimilar BLA For ABP 980 To FDA (RTTNews)
31.07.17	Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration (PR Newswire)
28.07.17	Amgen Announces 2017 Third Quarter Dividend (PR Newswire)
28.07.17	AGRX At FDA Altar Again, AZN Falls As MYSTIC Fails, VBIV Delivers A Good Shot (RTTNews)
27.07.17	FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events (PR Newswire)
25.07.17	Amgen Inc. Reports 12% Gain In Q2 Bottom Line (RTTNews)
25.07.17	Amgen Increases 2017 Adj. EPS Guidance - Quick Facts (RTTNews)
25.07.17	Amgen Reports Second Quarter 2017 Financial Results (PR Newswire)
21.07.17	AEZS Gets Down To Serious Work, APVO Surges, FDA Tentative Nod For MRK (RTTNews)
21.07.17	Amgen Says FDA Accepts BLA For Aimovig (RTTNews)
20.07.17	FDA Accepts Biologics License Application For Aimovig™ (erenumab) (PR Newswire)
20.07.17	Amgen Announces Webcast of 2017 Second Quarter Financial Results (PR Newswire)
18.07.17	Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation (PR Newswire)
17.07.17	Technical Reports on Biotech Equities -- Amicus Therapeutics, Pulmatrix, Amgen, and Bioverativ (PR Newswire)
17.07.17	FDA Turns Down AMGN's Osteoporosis Drug, EBS Opens Wallet, TROV Plunges (RTTNews)
17.07.17	Amgen And UCB Say FDA Issues CRL For BLA For EVENITY (RTTNews)
17.07.17	Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US (PR Newswire)
14.07.17	Amgen Submits Applications In US, Europe To Include OS Data In KYPROLIS Label (RTTNews)
14.07.17	FDA Panel Backs 2 Biosimilars, ALDR Abuzz, MDXG Q2 Revenue Grows 33% (RTTNews)
13.07.17	Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab) (PR Newswire)
13.07.17	NVS Gets Thumbs Up, Two Biosimilar Candidates To Face FDA Panel, VKTX On Track (RTTNews)
12.07.17	Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün
22.11.24		Gewinne in Frankfurt: SDAX zum Handelsende freundlich
22.11.24		EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück
22.11.24		Optimismus in Frankfurt: SDAX steigt am Nachmittag
22.11.24		Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag
22.11.24		Börse Frankfurt in Grün: TecDAX am Freitagnachmittag mit grünem Vorzeichen

22.11.24

Handel in Frankfurt: TecDAX letztendlich in Grün

22.11.24

Gewinne in Frankfurt: SDAX zum Handelsende freundlich

22.11.24

EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück

22.11.24

Optimismus in Frankfurt: SDAX steigt am Nachmittag

22.11.24

Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag

22.11.24

Börse Frankfurt in Grün: TecDAX am Freitagnachmittag mit grünem Vorzeichen